Integral Derivatives’s Achillion Pharmaceuticals ACHN Stock Holding History

Integral Derivatives’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-25,200	Closed	-$309K	–	1485
2014 Q4	$309K	Buy	+25,200	New	+$308K	0.01%	1069
2014 Q1	–	Sell	-15,600	Closed	-$52K	–	1674
2013 Q4	$52K	Buy	+15,600	New	+$45.3K	﹤0.01%	1432

Other funds holding ACHN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Integral Derivatives's ACHN Position: Q1 2018 in Review

Integral Derivatives sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 15,368 shares — an estimated $44K sold.

Integral Derivatives first reported a position in ACHN in Q4 2013 and held it in 6 quarters. The position peaked at $118K in Q2 2014. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

Integral Derivatives reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 15,368 Achillion Pharmaceuticals shares in Q1 2018, an estimated $44K.
Integral Derivatives first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Integral Derivatives's Achillion Pharmaceuticals position peaked at $118K in Q2 2014.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.